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Impaired immunologic recovery (IR) after hematopoietic stem cell transplantation (HSCT) is associated with
increased risk for infections and relapse. Stem cell source and graft manipulation inﬂuence the kinetics of IR.
Partial T cell depletion of peripheral blood stem cell (PBSC) grafts is a novel alternative method of graft
manipulation for children. We compared IR in children undergoing HSCT for hematologic malignancies
receiving either T celledepleted (TCD)-PBSCs (n ¼ 55) or umbilical cord blood (UCB) (n ¼ 21) over a 7-year
period at a single institution. PBSC grafts underwent ex vivo negative selection for CD3þ cells using the Clin-
iMACS system with partial T cell add-back. Recovery of CD4þ T cells was signiﬁcantly delayed in TCD-PBSC
recipients compared with UCB recipients, owing to impaired CD4þ/CD45RAþ (naïve) T cell lymphopoiesis.
Recovery of total CD3þ cells and CD3þ/CD8þ cells was similar in the 2 groups. The TCD-PBSC recipients had
amarked deﬁcit in CD19þ and, to a lesser extent, IgA/IgM, owing to the need for B cell depletion of these grafts to
attenuate the risk of lymphoproliferative disease after TCD HSCT. There were no signiﬁcant between-group
differences in response to mitogen stimulation, time to independence from intravenous immunoglobulin
supplementation, or incidence of viral reactivation. Transplantation outcomes of relapse, transplantation-
related mortality, event-free survival, and overall survival were similar in the 2 groups. Efforts to enhance IR
after partial TCD-PBSC transplantation, such as selective ab T cell depletion, hold promise for further
improvement of this transplantation approach.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION expansion [6]. BM and PBSC grafts contain predominately
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the sole curative option for many children with
high-risk hematologic malignancies, but only approximately
30% of these children will have a matched related donor
(MRD). To broaden access to this treatment modality, the use
of alternative donors is increasing, including bone marrow
(BM) or mobilized peripheral blood stem cells (PBSCs) from
matched unrelated or partially matched related donors, as
well as unrelated umbilical cord blood (UCB). Immunologic
recovery (IR) after alternative donor allogeneic HSCT in
children is complex and dynamic, inﬂuenced by various
patient and transplantation-related factors, including age of
recipient and donor, indication for transplantation, condi-
tioning regimen, donor type, stem cell source, graft manip-
ulation, infection, and graft-versus-host disease (GVHD)
chemoprophylaxis, type, and treatment [1,2]. Impaired IR
increases the risk of serious infection [3] and relapse [4], and
is associated with decreased survival [5].
Donor type and stem cell source affect IR [2]. The type and
quantity of passenger lymphocytes infused as a component of
the graft differ by stem cell source and degree ofmanipulation.
Passenger lymphocytes provide initial lymphoid immunity
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13.08.003memoryTcells,whereasUCBgraftshaveahigherproportionof
naive T cells with differing immunobiology [7]. Graft manip-
ulationwitheitherpositiveornegative cell selection inﬂuences
this early thymus-independent lymphoid recovery by altering
the cellular composition of the graft [8-10].
In the second wave of IR that occurs several months after
transplantation, phenotypically naïve T cells that have
undergone maturation in the thymus emerge [11]. This
thymic-dependent process is heavily inﬂuenced by various
clinical factors known to affect thymic function, including
age [2], conditioning regimen (particularly irradiation), and
presence of GVHD [12]. Because these factors are inextricably
linked to donor type and cell source, the kinetics of IR
continue to be inﬂuenced by graft characteristics even late
after transplantation.
At our institution, all types of alternative donors are
considered, and the ultimate decision depends on HLA
matching, urgency, patient size, and other factors (eg, cyto-
megalovirus [CMV] status). In an effort to maintain the
beneﬁts of mobilized PBSCsdincluding rapid neutrophil and
platelet engraftment [13]dwhile mitigating the increased
risk of cGVHD owing to greater numbers of T cells in the graft
[14], we have used partial T cell depletion. Our current
method involves ex vivo negative selection for CD3þ cells
using the CliniMACS system (Miltenyi Biotec, Bergish-
Gladbach, Germany) with partial T cell add-back. To eval-
uate IR in recipients of alternative donor grafts, we compared
IR after HSCT using this graft typewith a concurrent cohort of
UCB recipientsdthe other major alternative donor source atTransplantation.
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depletion has resulted in relatively few unrelated donor BM
transplantations, so this group was not included because
meaningful statistical comparison was precluded by small
numbers. In addition, we focused our analysis on alternative
donor HSCT, given that IR after MRD HSCT has been exten-
sively characterized and is the preferred approach when
available. Comparison of IR between alternative graft types
may inform decisions regarding donor selection when an
MRD is unavailable.
MATERIALS AND METHODS
Patients and Transplantation Regimens
We retrospectively reviewed the charts of 76 consecutive children
undergoing ﬁrst allogeneic HSCT for a hematologic malignancy at our
hospital between March 2005 and December 2011. During this period, 55
children received TCD-PBSC grafts that had been CD3þ-depleted using the
CliniMACS system (clinicaltrials.gov identiﬁer NCT00579124), and 21
patients received UCB grafts. The protocol was approved by our hospital’s
Institutional Review Board, and written informed consent was obtained
from all patients and/or parents, as appropriate.
All patients with an acute hematologic malignancy were in morpho-
logical remission (complete remission [CR]) at the time of transplantation.
Myeloablative conditioning was provided either with cyclophosphamide
60 mg/kg/day for 2 days and total body irradiation (TBI) 200 cGy twice daily
for 3 days (80.3%) or with cyclophosphamide and busulfan 0.8 to 1 mg/kg
every 6 hours for 16 doses, adjusted to achieve a target steady-state con-
centration of 750 to 1100 ng/mL (19.7%), both either with (81.6%) or without
thiotepa 5 mg/kg/day for 2 days.
A calcineurin inhibitor was administered as primary GVHD chemopro-
phylaxis in all patients. UCB recipients also received methylprednisolone
1 mg/kg/day starting on day þ7 and tapered starting at day þ21, as well as
granulocyte-colony stimulating factor (G-CSF; ﬁlgrastim) until the absolute
neutrophil count exceeded 2000 cells/mL. In the absence of GVHD, immu-
nosuppression was tapered starting on day þ100 (or earlier if there was
concern for declining chimerism). All patients received standard infectious
prophylaxis that was individually tailored to risk. Speciﬁcally, for CMV-
positive UCB recipients and CMV-positive TCD-PBSC recipients with CMV-
negative donors, foscarnet was used until engraftment occurred, at which
point it was replaced with valganciclovir, along with IVIG supplementation.
Otherwise, CMV prophylaxis was provided with IVIG supplementation
alone. Weekly plasma polymerase chain reaction testing for adenovirus,
CMV, and Epstein-Barr virus (EBV) was performed on all patients from
day þ7 up to day þ100 and as indicated thereafter; testing for additional
viruses was based on clinical indications.
Graft Manipulation
TCD-PBSC grafts were obtained by leukapheresis of peripheral blood
mononuclear cells after G-CSF stimulation. CD3þ depletion was performed
by negative selection using the automated CliniMACS device, as described
previously [15,16]. To mitigate the risk of post-transplantation lymphopro-
liferative disease, all PBSC grafts underwent some form of B cell depletion,
either ex vivo or in vivo. Before the availability of beads conjugated to anti-
CD19 antibodies, 38 patients received rituximab 375 mg/m2/dose on
days 1 and þ7; thereafter, grafts were depleted of B cells during ex vivo
manipulation (n ¼ 17). The number of CD3þ cells added back at the time of
the stem cell product infusion was determined by the degree and nature of
HLA mismatching and disease status, ranging from 0.2 to 8  105 cells/kg of
recipient weight (median, 1  105 cells/kg). The majority of patients (67%)
received between 1  105 and 3  105 cells/kg. In general, patients with
high-risk leukemia, less HLA disparity, and malignancies associated with
greater graft-versus-leukemia effects (eg, chronic myelogenous leukemia
[CML]) received higher CD3þ cell doses. Of the 7 patients who received
>3  105 cells/kg, 4 were 10/10 HLA matches, and all had CML, juvenile
myelomonocytic leukemia, or acute leukemia with evidence of minimal
residual disease at the time of transplantation. Recipients of low CD3þ cell
doses generally had 2 HLA antigen mismatches and were in durable CR.
Measurement of Immunologic Recovery
Formal assessments of immunologic recovery were made at 4, 8, 12, and
24 months after HSCT as the standard of care. Monoclonal antibodies to
surface antigens were used in ﬂow cytometry analysis to deﬁne the
following immunophenotypes: CD3/CD16þ and/or CD56þ (natural killer
[NK] cells), CD3þ (T cells), CD3þ/CD4þ (CD4þ T cells), CD3þ/CD8þ (cytotoxic
T cells), CD4þ/CD45RAþ (naïve CD4þ Tcells), CD4þ/CD45ROþ (memory CD4þ
T cells), CD19þ (B cells), and CD20þ (B cells). From these data, the ratios ofCD4þ cells to CD8þ cells (4:8) and that of naïve cells tomemory cells (RA:RO)
were calculated. Immunoglobulins (IgG, IgA, and IgM) were measured at the
same intervals by standard nephelometry. The time to independence from
intravenous gamma globulin (IVIG) supplementation was based on the
interval between day 0 and the last dose of IVIG, in days. Patients received
supplemental IVIG until the IgG level was maintained at >500 mg/dL
without support.
The response of peripheral blood mononuclear cells to stimulation with
themitogensphytohemagglutinin (PHA), pokeweed (PWM), and concanavalin
A (ConA) was measured at 8, 12, and 24 months post-transplantation. Results
are reportedas ratiosofpatient to control countsperminute (CPMrel); a normal
response was considered to be 50% of normal (CPMrel 0.5).
Among the subjects alive at 1 year, published age-based ranges in
healthy children for number of total lymphocytes, CD3þ cells, CD16þ/CD56þ
cells, CD3þ/CD4þ cells, CD3þ/CD8þ cells, and CD19þ cells were used to
deﬁne patients who were in at least the 5th percentile as “normal” [17].
Deﬁnitions of Transplantation Outcomes
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days on
which the peripheral blood absolute neutrophil count was500 cell/uL, and
platelet engraftment was deﬁned as the ﬁrst of 7 consecutive days with an
unsupported platelet count 20,000 cells/uL. Pre-engraftment bacteremia
was deﬁned as any positive blood culture obtained between the time of
initiation of the conditioning regimen and neutrophil engraftment. Viral
reactivations were included only if they were considered clinically signiﬁ-
cant, as deﬁned by either the need for antiviral therapy or the presence of
associated clinical manifestations. Untreated reactivations or infections
without clinical disease (eg, human herpesvirus-6 [HHV6] viremia without
symptomatic disease) were not counted.
Staging and grading of acute GVHD (aGVHD) and chronic GVHD
(cGVHD) was based on Center for International Blood and Marrow Trans-
plant Research guidelines. Patients who developed GVHD after donor
lymphocyte infusion (DLI) were considered to have GVHD. The time to
cessation of immunosuppressive therapy (IST) was deﬁned as the ﬁrst time
after HSCT or diagnosis of aGVHD or cGVHD at which the patient achieved
freedom from immunosuppressive medications for at least 1 month.
Relapse was deﬁned as morphological evidence of recurrent disease in
the peripheral blood or BM. Patients with mixed chimerismwho responded
to DLI were not considered to have relapsed. Transplantation-related
mortality (TRM) was deﬁned as all nonrelapse deaths. Event-free survival
was calculated based on the following events: relapse, TRM, or DLI.
Statistical Analysis
Baseline demographic and transplant characteristics were compared
using Fisher exact tests for categorical data and Wilcoxon rank-sum for
continuous variables. Theoutcomevariables of absolute lymphocyte numbers,
4:8 and RA:RO ratios, immunoglobulin levels, and mitogen responses were
logarithmically (base 10) transformed to obtain data showing symmetric
distribution. All analyses of the primary outcome measures of these variables
were performed on these transformed values. A linear mixed effects model
wasﬁtted to each outcome variable using ProcMixed in SAS 9.2 (SAS Institute,
Cary, NC). The model included group, time, and group-by-time interaction as
ﬁxed effects, along with a random intercept and a random slope for each
patient. This approach accounts for potential correlations among repeated
measurements, and was used to test differences between TCD-PBSC and UCB
recipients and differences between patients with and without cGVHD.
Two multivariate models were constructed to control for potential
confounders. The ﬁrst model incorporated pretransplantation variables with
a known association with IR after HSCT: age, sex, disease category (acute
lymphoblastic leukemia, acute myelogenous leukemia, other), conditioning
regimen (TBI, no TBI), HLA disparity (any mismatch, fully matched), and
receipt of antithymocyte globulin. A second model incorporated all of these
variables with the addition of cGVHD, the sole post-transplantation variable
included in multivariate analysis.
Differences in the proportion of patients reaching age-based normal
lymphocyte levels and mitogen response (as deﬁned above) were assessed
using the Fisher exact test. The following separate exposures were used:
UCB and TCD-PBSC; aGVHD grade II-IV and no aGVHD/grade I; cGVHD and
no cGVHD; and use of IST and no IST at 1 year.
The Kaplan-Meier method was used to estimate overall survival (OS)
and event-free survival (EFS), and differences between groups were tested
using the log-rank statistic. Patients who were event-free were censored at
the time of last follow-up. Cumulative incidence curves were generated for
relapse and TRM, adjusting for the other outcome as a competing risk.
Differences between the groups were tested using Gray’s test [18].
All statistical tests were 2-sided, with a signiﬁcance level of P < .05. All
analyses were performed using Stata 12.1 (StataCorp, College Station, TX) or
SAS 9.2.
Table 1
Demographic and Transplantation Characteristics
Characteristic All Patients TCD-PBSC UCB P Value
Number 76 55 21
Age, yr, median (IQR) 9 (5-14) 11 (7-16) 5 (1-7) <.001
Female sex, n (%) 39 (51.3) 28 (50.9) 11 (52.4) NS
Ethnicity, n (%) NS
White 44 (57.9) 30 (54.6) 14 (66.7)
Black 10 (13.2) 10 (18.2) 0
Other 22 (29.0) 15 (27.3) 7 (33.3)
Disease, n (%) NS
Acute lymphoblastic leukemia 30 (39.5) 22 (40.0) 8 (38.1)
Acute myelogenous leukemia 19 (25.0) 13 (23.6) 6 (28.6)
CML 7 (9.2) 7 (12.7) 0
Myelodysplastic syndrome 15 (19.7) 10 (18.2) 5 (23.8)
JMML 3 (4.0) 2 (3.6) 1 (4.8)
Bilineage 1 (1.3) 1 (1.8) 0
Other 1 (1.3) 0 1 (4.8)
Remission status, n (%) NS
CR1 27 (50.9) 22 (57.9) 5 (33.3)
CR2þ 26 (49.1) 16 (42.1) 10 (66.7)
Conditioning, n (%) .003
Cyclophosphamide/TBI  thiotepa 61 (80.3) 49 (89.1) 12 (57.1)
Busulfan/cyclophosphamide  thiotepa 15 (19.7) 6 (10.9) 9 (42.9)
JMML indicates juvenile myelomonocytic leukemia; NS, not signiﬁcant.
P values are based on Wilcoxon rank-sum or Fisher exact tests.
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Demographic and Transplantation Characteristics
The 2 groups were well matched overall for major de-
mographic and transplantation-related variables (Table 1).
However, as expected, the median age at transplantation
was signiﬁcantly younger in UCB recipients than in TCD-
PBSC recipients (5 years versus 11 years; P < .001). In
addition, TCD-PBSC recipients were more likely to receive
a TBI-containing preparative regimen (P ¼ .003). Antithy-
mocyte globulin was administered to 8 UCB recipients
(38.1%) as part of conditioning (proximal) and 4 TCD-PBSC
recipients (7.3%) several weeks before transplantation
(distal) in patients who had not received previous chemo-
therapy (eg, patients with myelodysplastic syndrome or
CML) (P ¼ .003).
Graft Characteristics
Graft characteristics are summarized in Table 2. The
overall proportion of HLA-mismatched donorerecipient
pairs was similar in the 2 groups, but the TCD-PBSC recip-
ients had more HLA-DRB1 mismatches. Total nucleated and
CD34þ cell doses were within expected ranges based on
stem cell source. The median CD3þ cell dose was more than
100-fold lower in TCD-PBSC grafts compared with UCB
grafts.Table 2
Graft Characteristics
Characteristic TCD-PBSC
Donor type, n (%)
Matched sibling donor 0
Unrelated donor 49
Mismatched related donor 6
HLA disparity, n (%)
Any mismatch 39
2 loci 24
DR mismatch 6
Graft composition, cells/kg, median (IQR)
Total nucleated cells 2.52  108
CD34 cells 6.5  106
CD3 cells 1  105Engraftment and Innate Immunity
Neutrophil recovery occurred signiﬁcantly earlier in the
TCD-PBSC recipients compared with the UCB recipients
(median, 15 days versus 19 days; P < .001), as did platelet
engraftment (median, 18 days versus 35 days; P < .001). All
patients experienced myeloid engraftment, but 3 TCD-PBSC
recipients (5.5%) and 2 UCB recipients (9.5%) did not ach-
ieve platelet engraftment owing to early TRM. NK cell
numbers were signiﬁcantly higher in UCB recipients at all
time points, but both groups exhibited robust normal early
levels that gradually trended down over time after HSCT
(Figure 1A).
Adaptive Immunity
UCB recipients had signiﬁcantly higher total lymphocyte
numbers compared with TCD-PBSC recipients up to 2 years
post-HSCT (Figure 1B). Although more UCB recipients than
TCD-PBSC recipients attained age-speciﬁc normal total
lymphocyte levels by 1 year post-HSCT, the differnece was
not statistically signiﬁcant (78.6% versus 60.5%; P ¼ .33)
(Table 3).
T cells
Absolute numbers of T cells were comparable in the
2 groups at all time points (Figure 1C); however, by 1 yearUCB
1 (4.8)
(89.1) 20 (95.2)
(10.9) 0
(70.9) 17 (81.0)
(43.6) 10 (47.6)
(10.9) 0
(3.43-7.08  108) 0.51  108 (0.24-0.72  108)
(4.92-8.74  106) 0.41  106 (0.19-0.5  106)
(1-2.67  105) 1.2  107 (0.6-2.3  107)
Figure 1. Levels of NK cells (A), total lymphocytes (B), and T cells (C) as a function of time after HSCT, by graft type. All lymphocyte numbers have been logarithmically
transformed and are presented as mean with 95% CI error bars. P values based on linear mixed-effect modeling: *P < .001; #P < .01; ^P < .05.
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normal T cell levelsdthe lowest percentage of any cell
typedcompared with 78.6% of UCB recipients (P ¼ .11)
(Table 3). Within the T cell compartment, absolute levels of
cytotoxic T cells (Figure 2B) and the proportion reaching
normal levels by 1 year were nearly identical in the 2 groups
(Table 3). In contrast, CD4þ T cell numbers were lower in
TCD-PBSC recipients up to 2 years post-HSCT (Figure 2A).
Given the relative paucity of CD4þ T cells in TCD-PBSC
recipients, the 4:8 ratio was generally lower than that seen
in UCB recipients. In both groups, this ratio trended down-
ward (to more normal levels) as cytotoxic T cells gradually
recovered (Figure 2E).
Within the CD4þ Tcell compartment, naïve Tcell recovery
was impaired in TCD-PBSC subjectsdpersisting up to 2 years
post-HSCTdwhereas memory T cell recovery was compa-
rable in the 2 groups (Figure 2C and D). The ratio of naïve to
memory CD4þ T cells (RA:RO ratio) reﬂects these trends.
Although both groups showed a gradual increase in the
RA:RO ratio as naïve T cells emerged (presumably after
thymic maturation), this increase was earlier and more
robust in the UCB recipients, resulting in a signiﬁcantly
higher ratio at 8 and 12 months post-HSCT (Figure 2F).Table 3
Proportion of Patients Reaching Normal Levels by 1 Year by Graft Type
TCD-PBSC (n ¼ 34) UCB (n ¼ 14) P Value
Cell type
Absolute lymphocyte
count
60.5 78.6 .33
CD3þ 50 78.6 .11
CD3þ/CD4þ 67.7 78.6 .51
CD3þ/CD8þ 70.6 64.3 .74
CD19þ 64.7 92.9 .073
Mitogen
PHA 44.0 54.6 .56
PWM 52 45.5 .72
ConA 60.0 63.6 .84
Data are percentage of patients alive at 1 year with normal lymphocyte
levels or mitogen response. For lymphocyte subsets, normal is deﬁned as
5th percentile of age-based normal levels. For mitogen response, normal is
deﬁned as 50% of the control response. All P values are based on the Fisher
exact test.Humoral immunity
The most pronounced difference between the 2 groups
was in B cells, which were profoundly impaired in the TCD-
PBSC recipients, in terms of both absolute numbers
(Figure 3A) and the proportion of patients achieving normal
levels (Table 3). This deﬁcit was seen in both pre-Ig and post-
Ig class-switched memory B cell subsets (CD19þ/CD27þ/IgDþ
and CD19þ/CD27þ/IgMþ, respectively). Of note, in the TCD-
PBSC recipients, memory B cells (CD27þ) did not demon-
strate evidence of substantial reconstitution until 1 year
post-HSCT, whereas in UCB recipients, levels began to
increase as early as 8 months post-HSCT and demonstrated
a consistent linear trend (data not shown).
IgM levels were lower in TCD-PBSC recipients than in UCB
recipients up to 2 years post-HSCT (Figure 3B). IgA levels
converged earlier, with relatively comparable levels as soon
as 8 months, although the between-group difference
remained signiﬁcant until 1 year (Figure 3C). The average
time to independence from IVIG supplementation was
157 days in the TCD-PBSC recipients and 178 days in the UCB
recipients (P ¼ .73).
Response to mitogens
In contrast to the sometimes marked differences in
absolute numbers of various lymphocyte subsets, the
response to mitogen stimulation was remarkably similar in
the 2 groups. As shown in Figure 4, there was no statistically
signiﬁcant difference in response to any mitogen between
the groups at 8, 12, or 24 months post-HSCT, regardless of
mitogen. Although some variation, generally functional
recovery (50% of control) was achieved in about half of
patients in both groups by 1 year (Table 3). Notably, TCD-
PBSC recipients seemed to perform comparably to UCB
recipients even in response to mitogens requiring competent
B cell function (PWM).
GVHD and IST
aGVHD
Rates of any aGVHD were similar in the 2 groups (UCB,
66.7%; TCD-PBSC, 76.4%; P ¼ .537). However, UCB recipients
tended to have higher incidences of grade II-IV andgrade III-IV
Figure 2. Levels of CD4þ T cells (A), cytotoxic T cells (B), naïve CD4þ T cells (C), and memory CD4þ T cells (D), and 4:8 ratio and RA:RO ratio as a function of time after
HSCT (E), by graft type. All lymphocyte numbers have been logarithmically transformed and are presented as means with 95% CI error bars. 4:8 and RA:RO are
untransformed and presented as mean with SEM error bars. P values based on linear mixed-effect modeling: *P < .001; #P < .01; ^P < .05.
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PBSC recipients (47.3% and 18.2%, respectively), although
neither of these differences was statistically signiﬁcant.
Because the presence of grade II-IV aGVHD did not affect
the numbers of any of the lymphocyte subpopulations
measured, with the exception of B cells (data not shown),
and did not affect the proportion of patients reaching normal
levels by 1 year (Table 4), aGVHD was not included in the
multivariate analysis.Figure 3. Levels of B cells (A), IgM (B), and IgA (C) as a function of time after transplan
and are presented as means with 95% CI error bars. P values based on linear mixed-cGVHD and immunosuppression
The incidence of extensive cGVHD in evaluable patients
was similar in the 2 groups (TCD-PBSC, 15.2%; UCB, 21.4%;
P ¼ .69), reﬂected in the nearly identical proportions of
patients in the 2 groups (approximately 30%) who remained
alive and on IST at 1 year post-HSCT. The median time to
cessation of IST was 195.5 days (IQR, 127.5 to 400.5 days) in
TCD-PBSC recipients and 159 days (IQR, 129 to 456 days) in
UCB recipients (P ¼ .96). Eight TCD-PBSC recipients requiredt, by graft type. All lymphocyte numbers have been logarithmically transformed
effect modeling: *P < .001; #P < .01; ^P < .05.
Figure 4. Responses to mitogen stimulation based on graft time by time after HSCT, by graft type. (A) PHA. (B) PWM. (C) ConA. Data are presented as mean CPMrel
with SEM error bars. No signiﬁcant between-group differences were detected.
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patients who were salvaged and subsequently attained
durable CR experienced cGVHD (extensive in 2 patients).
Patients with cGVHD and those receiving IST at 1 year
post-HSCT were statistically signiﬁcantly less likely than
those without cGVHD and off IST to achieve normal levels of
CD4þ T cells and B cells by 1 year (Table 4). A comparison of
lymphocyte numbers in patients with cGVHD and those
without cGVHD showed lower levels of naïve CD4þ T cells at
12 and 24 months in affected patients and lower levels of B
cells at all times in affected patients up to 2 years post-HSCT
(Figure 5B and C). Absolute numbers of other lymphocytes
did not differ signiﬁcantly by cGVHD status, even when the
entire CD4þ T cell pool was examined (Figure 5A).
The response to stimulation with PWM at 1 year post-
HSCT was severely reduced in patients with cGVHD
compared with those without cGVHD. There was a trend
toward the same effect after PHA stimulation, although this
did not reach statistical signiﬁcance (Table 4). This discrep-
ancy in the effect of cGVHD on mitogen response is likely
attributable to the fact that PWM response reﬂects both B
cell and T cell function, whereas PHA is more T cellespeciﬁc.Table 4
Proportion of Patients Achieving Normal Lymphocyte Levels and Mitogen Respons
aGVHD cGVHD
Grade 0-I
(n ¼ 22)
Grade II-IV
(n ¼ 25)
P Value None
(n ¼ 22)
Cell type
Absolute lymphocyte count 61.5 68.0 .63 68.2
CD3þ 50.0 64.0 .33 57.1
CD3þ/CD4þ 77.3 64.0 .32 85.7
CD3þ/CD8þ 68.2 68.0 .99 66.7
CD19þ 77.3 68.0 .48 90.5
Mitogen
PHA 50.0 42.1 .64 62.5
PWM 56.3 47.4 .60 68.8
ConA 56.3 63.2 .68 68.8
Data are percentage of patients alive at 1 year with known GVHD status with norma
deﬁned as5th percentile of age-based normal levels. For mitogen response, norm
exact test.Multivariate Analysis
After adjustment using both models, the between-group
differences in absolute numbers of naïve CD4þ T cells and B
cells, IgM, IgA, and RA:RO persisted at all previously signiﬁ-
cant time points. Differences in NK cells, CD4þ Tcells, and 4:8
ratio were abrogated in both multivariate models. This
suggests that the differences in CD4þ T cell and NK cell
recovery between UCB and TCD-PBSC recipients are medi-
ated by factors beyond graft source or manipulation.
Infection and Transplantation Outcomes
Infection
The UCB recipients had a higher rate of pre-engraftment
bacteremia than the TCD-PBSC recipients, although the
difference was not statistically signiﬁcant (28.6% versus
16.4%; P ¼ .33). Although most viral reactivations occurred
early (median, dayþ36.5; IQR, day þ19 to day þ71) and thus
reﬂect early IR, we compared the incidences of CMV, EBV,
HHV6, and adenovirus in the 2 groups as a proxy for quality
of overall IR. Rates of recipient CMV seropositivity and inci-
dence of CMV reactivationwere comparable in the TCD-PBSC
and UCB recipients (18.2% versus 14.3%), as were thee at 1 Year, by GVHD Status
IST
Limited/Extensive
(n ¼ 27)
P Value No (n ¼ 32) Yes (n ¼ 16) P Value
59.3 .52 71.9 50.0 .14
56.0 .94 63.3 42.9 .20
56.0 .029 83.3 42.9 .006
68 .92 66.7 71.4 .75
56.0 .019 83.3 50.0 .021
33.3 .089 50 44.4 .78
33.3 .039 58.3 44.4 .48
50 .27 66.7 55.6 .56
l lymphocytes levels or mitogen response. For lymphocyte subsets, normal is
al is deﬁned as 50% of the control response. P values are based on the Fisher
Figure 5. Levels of CD4þ T cells (A), naïve CD4þ T cells (B), and B cells (C) as a function of time after HSCTon, by cGVHD status. All lymphocyte numbers have been
logarithmically transformed, and are represented as means with 95% CI error bars. P values based on linear mixed-effect modeling: *P < .001; #P < .01; ^P < .05.
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versus 4.8%). All patients with EBV reactivation were suc-
cessfully preemptively treated with rituximab before clini-
cally evident lymphoproliferative disease developed; these
patients were included in the analysis of B cell reconstitution.
Adenovirus infection was more common in the UCB recipi-
ents (19.1% versus 5.5%; P¼ .087). When all viral infections or
reactivations were examined in aggregate, the incidence of
any viral infection was nearly identical in the TCD-PBSC and
UCB recipients (43.6% versus 47.6%).
Relapse, TRM, and survival
There were no between-group differences in the com-
peting risk-adjusted cumulative incidence of either relapse
or TRM, or in the Kaplan-Meier survivor probabilities of OS
and EFS. The 2-year OS was 65.2% (95% conﬁdence interval
[CI], 50.3% to 76.6%) in the TCD-PBSC recipients and 60.6%
(95% CI, 36.1% to 78.2%) in the UCB recipients, and the 2-year
EFS was 48.5% (95% CI, 34.2% to 61.4%) in the TCD-PBSC
recipients and 54.6% (95% CI, 30.3% to 73.5%) in the UCB
recipients.
DISCUSSION
Quality IR after HSCT is critical for protection against both
infection and relapse, and is associated with improved
survival. Stemcell source andgraftmanipulation are known to
inﬂuence the kinetics of IR [19-23]. The advantages of PBSCs as
a stem cell source are achieved at the expense of a higher
incidence of cGVHD [13,14]. Conversely, UCB grafts generally
are associatedwith a low incidence ofGVHDeven in the faceof
greaterHLAdisparity, butwith slower engraftment andhigher
risk of graft failure [24,25]. The present study compared the
kinetics of IR in pediatric recipients of a relatively novel graft
type (partial TCD-PBSC) and recipients of a more established
alternative donor source (UCB). These 2 graft types represent
the predominant alternative donor sources at our institution
and are used in patients with high-risk malignancies when an
HLA-matched sibling donor is unavailable.
Strengths of this study include the relatively large
sample sizes, long duration of follow-up, and homogenoustransplantation regimens in the 2 study groups, who under-
went HSCT for similar indications and received comparable
conditioning and supportive care. This permitted a focused
evaluation of the effects of stem cell source and ex vivo
manipulation on IR.
T cell recovery was generally impaired after TCD-PBSC
HSCT, but a close examination of critical T cell subsets
elucidates key disparities between the 2 study groups. TCD-
PBSC recipients demonstrated a pronounced naïve CD4þ
T cell lymphopenia that accounted for much of the between-
group disparity in CD4þ T cell IR. Moreover, despite 2-log
fewer passenger T cells in TCD-PBSC grafts, the number of
memory T cells was similar in TCD-PBSC recipients and UCB
recipients at all time points, likely related to the relative
paucity of passenger memory T cells in UCB grafts. Because
much of the early T cell expansion after HSCT is driven by
homeostatic peripheral expansion of passenger lymphocytes
infused with the graft, the immunobiology of the graft and
the process of ex vivo graft manipulation has important
implications for the kinetics of early IR [8-10]. In PBSC (and
BM) grafts, these passenger lymphocytes characteristically
express a memory phenotype; however, UCB grafts contain
a relatively higher percentage of naïve T cells [7]. Our results
are consistent with these principles.
In a second wave of T cell lymphopoiesisdtypically
occurring 8 to 12 months after HSCTdthymic-dependent
maturation occurs, producing naïve T cells with diverse TCR
repertoires. Clinical factors known to affect thymic function,
such as age [2,26], GVHD [12,27], and the conditioning
regimen, strongly inﬂuence this process. Both groups expe-
rienced an increase in the naïve T cell pool between 4 and
8 months, resulting in a prominent increase in the RA:RO
ratio at this time; however, this phenomenon was more
pronounced in the UCB recipients, suggesting superior
thymic-mediated naïve T cell recovery. It is possible that this
difference is confounded by the fact that compared with
TCD-PBSC recipients, UCB recipients are younger and less
likely to have received TBI-based conditioning, both of which
inﬂuence thymic function. However, differences in naïve
CD4þ T cells persisted in the multivariate analysis which
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graft biology as the overriding driving force.
Exposure of donor lymphohematopoietic cells to G-CSF
during mobilization is known to inﬂuence cytokine release
and immunologic function, possibly contributing to the CD4þ
cell deﬁcit seen in TCD-PBSC recipients. Preclinical data
indicate that the balance of CD4þ subsetsdincluding Th1,
Th17, and regulatory T cellsdcan vary greatly and potentially
inﬂuence the development of GVHD in animal models [28].
Because TCD is nonselective, future studies evaluating the
proportion of each subset within the CD4þ compartment and
the post-HSCT homeostatic expansion of these subsets will
be of signiﬁcant clinical interest. Moreover, our ﬁndings are
limited by our assumption that naïve CD4þ T cells represent
recent thymic emigrants; however, more speciﬁc methods
exist for deﬁning this population of thymically matured
T cells, including TCR rearrangement excision circles, further
immunophenotyping (eg, CCR7þ, CD62Lþ), and spectratyp-
ing of the TCR repertoire diversity [2].
In contrast to these between-group differences in the
CD4þ T cell pool, recovery of cytotoxic T cells was equivalent
in the 2 groups. However, because UCB recipients are known
have impaired cytotoxic T cell recovery compared with other
unrelated donors [29,30], this still likely represents a major
deﬁciency in IR after TCD-PBSC HSCT.
The pattern of B cell recovery demonstrates a profound
and prolonged relative B cell lymphopenia in TCD-PBSC
recipients compared with UCB recipients across all B cell
subsets. The UCB recipients demonstrated rapid and robust
quantitative B cell recovery, with more than 90% achieving
normal levels by 1 year, in agreement with previous reports
[24,31]. Compounding this disparity is the need to deplete the
TCD-PBSC grafts of B cells to mitigate the risk of EBV-related
lymphoproliferative disease. Early rituximab exposure after
HSCT has been shown to profoundly affect humoral immu-
nity [32]. Somewhat reassuringly, differences in IgM and IgA
levels were less pronounced, and the time to independence
from IVIG supplementation was similar in the 2 groups.
Notably, despite these disparate patterns of lymphocyte
and immunoglobulin recovery, there were no major
between-group differences in the incidence of early viral
reactivation or proliferative response of PBMC to mitogen
stimulation, suggesting comparable functional immunity.
Both of these measures serve as surrogates for immune
function and reﬂect both humoral and cellular immunity
[33]. Response to mitogen stimulation was notably similar
evenwith PWM, which requires B cell competency, and with
ConA, a mitogen associated with high sensitivity in identi-
fying T cell immunodeﬁciencies [33]. A lag between quanti-
tative lymphocyte recovery and actual functional recovery
after transplantation has been well reported, but a more
pronounced lag after UCB HSCT owing to the “immaturity” of
passenger graft immune cells could possibly explain our
ﬁndings. Alternatively, if the passenger lymphocytes in
a TCD-PBSC graft contain a high proportion of central
memory cells, then the initial homeostatic peripheral
expansion may be sufﬁcient to confer early protection
against viruses, as would passive infusion of high numbers of
effector memory cells, which would not be expected to
expand signiﬁcantly [34]. Moreover, NK cells contribute to
early antiviral (and antitumor) protection as well as to
engraftment [35], and these cells recovered early in both
groups. Early and robust expansion of NK cells is also seen in
autologous HSCT and may help explain the low incidence of
viral reactivation in these recipients as well. Our data on theincidence of viral reactivation are limited by the fact that
most viral reactivations occurred early (median, day þ36.5),
before our ﬁrst assessment of IR.
GVHD exerts deleterious effects on lymphocytes by direct
lymphocyte toxicity [36], impairment of thymic function
[12,27], and its treatment with IST. We did not detect a major
effect of aGVHD on immunologic recovery, despite universal
treatment of grade III-IV aGVHD with 2- or 3-drug regimen
that included systemic steroids. We speculate that this lack of
association can be attributed to the relatively late initial
assessment (at 4 months) of IR in our study. Moreover, much
of the aGVHD seen in the present study was steroid-
responsive and did not necessarily require additional IST or
long-term steroid use. On the other hand, cGVHD signiﬁcantly
impaired CD4þ T cell and B cell recovery. Within the CD4þ T
cell compartment, naïve T cells seem to be preferentially
suppressed by cGVHD. This is likely attributable in part to
direct thymic damage by alloreactive cellular mediators (with
resulting impairment of thymic-dependent naïve cell recon-
stitution), supported by the fact that differences do not
emerge until after 8 months post-HSCT when thymic-
dependent lymphopoiesis becomes a major contributor to
IR. In addition, this effect likely is partially mediated by
pharmacologic treatment of cGVHD, given that patients who
remained on IST at 1 year post-HSCT had even more pro-
nounced CD4þ T cell deﬁcits. The deleterious effect of cGVHD
on B cells as a result of both direct toxicity and reduced
presence of support cells has been described as well [37].
Despite apparent differences in certain aspects of IR, the
major clinical outcomes of relapsedTRM, EFS, and OSdwere
similar in our 2 groups of HSCT recipients. This suggests that
the process of TCD does not negate the graft-versus-
leukemia effects of PBSC HSCT and that the impaired IR
seen in these graft recipients does not substantively increase
the risk of infection-related TRM compared that in with UCB
recipients. The use of this graft manipulation method holds
promise for effective application of HSCT in children with
high-risk hematologic malignancies who lack an HLA-
matched related donor and who do not have an 8/8 or 10/
10 high-resolution unrelated donor match; almost three-
quarters of our TCD-PBSC recipients were mismatched at
1 HLA locus, and many were mismatched at multiple loci.
However, ongoing efforts to enhance IR after TCD-PBSC HSCT,
such as selective depletion of abþ T cells [38], are important
to further improve outcomes using this transplantation
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